Showing 181 - 200 results of 804 for search '"Inflammatory bowel disease"', query time: 0.09s Refine Results
  1. 181

    Prospective Evaluation of Neutrophil Autoantibodies in 500 Consecutive Patients with Inflammatory Bowel Disease by Hugh Freeman, Brenda Roeck, Dana Devine, Cedric Carter

    Published 1997-01-01
    “…Previous studies have shown antineutrophil cytoplasmic autoantibodies (ANCA) in patients with inflammatory bowel disease (IBD). …”
    Get full text
    Article
  2. 182

    Prevalence of Joint Hypermobility and Patterns of Articular Manifestations in Patients with Inflammatory Bowel Disease by P. Vounotrypidis, E. Efremidou, P. Zezos, M. Pitiakoudis, E. Maltezos, N. Lyratzopoulos, G. Kouklakis

    Published 2009-01-01
    “…The objective is the investigation of Joint Hypermobility (JH) and the Hypermobility Syndrome (HMS) in patients with inflammatory bowel disease (IBD). Methods. We examined 83 patients with IBD and 67 healthy individuals for the presence of JH. …”
    Get full text
    Article
  3. 183

    Fecal Calprotectin Use in Inflammatory Bowel Disease and Beyond: A Mini-Review by Bashaar Alibrahim, Mohammed I Aljasser, Baljinder Salh

    Published 2015-01-01
    “…The present article summarizes the experience with this test used in inflammatory bowel disease, as well as a variety of gastrointestinal disorders.…”
    Get full text
    Article
  4. 184

    Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease by Yao Wei, Weiming Zhu, Jianfeng Gong, Dong Guo, Lili Gu, Ning Li, Jieshou Li

    Published 2015-01-01
    “…Fecal microbiota transplantation improves quality of life significantly in patients with inflammatory bowel disease.…”
    Get full text
    Article
  5. 185
  6. 186

    Assessment tools for transition readiness in adolescents with inflammatory bowel disease: A scoping review. by YaHui Zuo, Mei Li, JinJin Cao, JiaNan Wang, WenQian Cai, Lu Zhang, Meng Li

    Published 2025-01-01
    “…<h4>Background</h4>Assessing the level of transition readiness in adolescents with inflammatory bowel disease is crucial; however, standardized research tools are lacking. …”
    Get full text
    Article
  7. 187
  8. 188

    Evaluation of the Clinical Efficacy of Prednisolone in the Treatment of Inflammatory Bowel Diseases with Different Dosage Methods by O. P. Alekseeva, S. V. Krishtopenko, A. A. Alekseeva

    Published 2023-05-01
    “…In this study were included 86 patients aged from 18 to 65 years with moderate or severe active inflammatory bowel disease (61 — UC, 25 — CD). All patients were treated with prednisolone at an initial daily dose from 30 to 60 mg with a subsequent tapering of dose. …”
    Get full text
    Article
  9. 189
  10. 190

    Quality improvement exercises in Inflammatory Bowel Disease (IBD) services: A scoping review. by Katie Ridsdale, Kajal Khurana, Azizat Temidayo Taslim, Jessica K Robinson, Faith Solanke, Wei Shao Tung, Elena Sheldon, Daniel Hind, Alan J Lobo

    Published 2024-01-01
    “…<h4>Objective</h4>Quality Improvement initiatives aim to improve care in Inflammatory Bowel Disease (IBD). These address a range of aspects of care including adherence to published guidelines. …”
    Get full text
    Article
  11. 191

    Assessing inflammatory protein factors in inflammatory bowel Disease using multivariable mendelian randomization by Qiang Su, Yun Lu, Song He, Jiang Liang, Song Huang, Yuanli He, Zhenxiang An

    Published 2025-01-01
    “…Abstract Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), decreases quality of life and causes disability. …”
    Get full text
    Article
  12. 192
  13. 193

    Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease by Carmen Stolwijk, Marieke Pierik, Robert Landewé, Ad Masclee, Astrid van Tubergen

    Published 2013-01-01
    “…BACKGROUND: Musculoskeletal symptoms belonging to the spectrum of ‘seronegative spondyloarthritis’ (SpA) are the most common extraintestinal manifestations in patients with inflammatory bowel disease (IBD) and may lead to important disease burden. …”
    Get full text
    Article
  14. 194
  15. 195
  16. 196

    Risk Factors for Worsening of Bone Loss in Patients Newly Diagnosed with Inflammatory Bowel Disease by Yi Yin, Xiaofeng Lu, Zhun Li, Song Liu, Lihua Shao, Lei Cao, Rui-Qing Liu, Liang-Yu Huang, Zhen-Xing Zhu, Zhen Guo, Yi Li, Wei-Ming Zhu

    Published 2022-01-01
    “…Bone loss is common in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the prevalence of metabolic bone disease in patients newly diagnosed with IBD and to identify the risk factors for bone loss over time. …”
    Get full text
    Article
  17. 197
  18. 198
  19. 199

    CUZD1 and Anti-CUZD1 Antibodies as Markers of Cancer and Inflammatory Bowel Diseases by Christos Liaskos, Eirini I. Rigopoulou, Timoklia Orfanidou, Dimitrios P. Bogdanos, Christos N. Papandreou

    Published 2013-01-01
    “…CUZD1, the CUB, and zona pellucida-like domains-containing protein 1, is a newly identified antigen of pancreatic autoantibodies (PAB) giving a reticulogranular pattern in patients with inflammatory bowel diseases, and in particular Crohn’s disease. …”
    Get full text
    Article
  20. 200

    The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases by Cheryl Kluthe, Jenkin Tsui, Donald Spady, Matthew Carroll, Eytan Wine, Hien Quoc Huynh

    Published 2018-01-01
    “…Medication nonadherence is a challenge in pediatric patients with inflammatory bowel diseases (IBD). Poor adherence can result in disease flare-ups, disease complicationstherapy escalation, and the need for corticosteroids. …”
    Get full text
    Article